OncoTherapy Science, Inc. (TYO:4564)
Japan
· Delayed Price · Currency is JPY 23.00
-1.00 (-4.17%)
May 2, 2025, 3:30 PM JST
OncoTherapy Science Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 945 | 527 | 1,117 | 1,836 | 2,899 | 4,713 | Upgrade
|
| Cash & Short-Term Investments | 945 | 527 | 1,117 | 1,836 | 2,899 | 4,713 | Upgrade
|
| Cash Growth | 58.03% | -52.82% | -39.16% | -36.67% | -38.49% | -2.96% | Upgrade
|
| Accounts Receivable | 92 | 35 | 123 | 399 | 152 | 29 | Upgrade
|
| Other Receivables | - | 153 | - | - | - | - | Upgrade
|
| Receivables | 92 | 188 | 123 | 399 | 152 | 29 | Upgrade
|
| Inventory | 69 | 73 | 99 | 231 | 41 | 24 | Upgrade
|
| Other Current Assets | 76 | 29 | 83 | 134 | 102 | 112 | Upgrade
|
| Total Current Assets | 1,182 | 817 | 1,422 | 2,600 | 3,194 | 4,878 | Upgrade
|
| Property, Plant & Equipment | - | - | - | - | 94 | 113 | Upgrade
|
| Long-Term Investments | 49 | 49 | 89 | 84 | 74 | 90 | Upgrade
|
| Other Intangible Assets | - | - | - | - | 4 | 6 | Upgrade
|
| Other Long-Term Assets | 1 | 1 | - | 1 | 2 | 1 | Upgrade
|
| Total Assets | 1,232 | 867 | 1,511 | 2,685 | 3,368 | 5,088 | Upgrade
|
| Current Income Taxes Payable | 252 | 141 | 318 | 558 | 174 | 218 | Upgrade
|
| Other Current Liabilities | 39 | 218 | 291 | 46 | 20 | 24 | Upgrade
|
| Total Current Liabilities | 291 | 359 | 609 | 604 | 194 | 242 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | - | - | 2 | 3 | Upgrade
|
| Other Long-Term Liabilities | 113 | 155 | 48 | 102 | 97 | 116 | Upgrade
|
| Total Liabilities | 404 | 514 | 657 | 706 | 293 | 361 | Upgrade
|
| Common Stock | 647 | 50 | 789 | 789 | 50 | 1,420 | Upgrade
|
| Additional Paid-In Capital | 26,919 | 26,322 | 24,793 | 24,793 | 24,054 | 22,684 | Upgrade
|
| Retained Earnings | -26,810 | -26,092 | -24,804 | -23,686 | -21,114 | -19,553 | Upgrade
|
| Comprehensive Income & Other | 72 | 73 | 76 | 83 | 85 | 176 | Upgrade
|
| Total Common Equity | 828 | 353 | 854 | 1,979 | 3,075 | 4,727 | Upgrade
|
| Shareholders' Equity | 828 | 353 | 854 | 1,979 | 3,075 | 4,727 | Upgrade
|
| Total Liabilities & Equity | 1,232 | 867 | 1,511 | 2,685 | 3,368 | 5,088 | Upgrade
|
| Net Cash (Debt) | 945 | 527 | 1,117 | 1,836 | 2,899 | 4,713 | Upgrade
|
| Net Cash Growth | 58.03% | -52.82% | -39.16% | -36.67% | -38.49% | -2.96% | Upgrade
|
| Net Cash Per Share | 3.81 | 2.48 | 5.80 | 9.79 | 16.44 | 28.91 | Upgrade
|
| Filing Date Shares Outstanding | 271.64 | 239.34 | 206.64 | 192.64 | 176.33 | 176.33 | Upgrade
|
| Total Common Shares Outstanding | 271.64 | 217.64 | 192.64 | 192.64 | 176.33 | 176.33 | Upgrade
|
| Working Capital | 891 | 458 | 813 | 1,996 | 3,000 | 4,636 | Upgrade
|
| Book Value Per Share | 3.05 | 1.62 | 4.43 | 10.27 | 17.44 | 26.81 | Upgrade
|
| Tangible Book Value | 828 | 353 | 854 | 1,979 | 3,071 | 4,721 | Upgrade
|
| Tangible Book Value Per Share | 3.05 | 1.62 | 4.43 | 10.27 | 17.42 | 26.77 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.